

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/00669</b> <b>(43) International Publication Date:</b> 9 January 1997 (09.01.97)
<b>(21) International Application Number:</b> PCT/EP96/02539 <b>(22) International Filing Date:</b> 12 June 1996 (12.06.96)  <b>(30) Priority Data:</b> 08/493,761 22 June 1995 (22.06.95) US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/493,761 (CIP) Filed on 22 June 1995 (22.06.95)  <b>(71) Applicant (for all designated States except US):</b> CIBA-GEIGY AG [CH/CH]; Klybeckstrasse 141, CH-4002 Basle (CH).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> TSAO, Fu-Pao [US/US]; 1361 Pinchurst Hunt, Lawrenceville, GA 30243 (US).  <b>(74) Common Representative:</b> CIBA-GEIGY AG; Patentabteilung, Klybeckstrasse 141, CH-4002 Basle (CH).		<b>(81) Designated States:</b> AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> COMPOSITIONS AND METHODS FOR STABILIZING POLYMERS		
<b>(57) Abstract</b>  Compositions and methods for reducing the decomposition rate of polymeric bioadhesives and viscosity enhancers, such as poly(acrylic acids). The compositions include at least one strong, stable chelating agent, preferably an organophosphorous compound such as diethylene triamine penta(methylene phosphonic acid). These biocompatible compositions are especially useful in the ophthalmic field.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

**COMPOSITIONS AND METHODS FOR STABILIZING POLYMERS****FIELD OF THE INVENTION**

This invention relates broadly to compositions and method for stabilizing polymers. In a preferred embodiment, the invention relates to stabilization of bioadhesives and viscosity enhancers in ophthalmic compositions.

**DESCRIPTION OF THE RELATED ART**

Water soluble and water swellable (i.e., hydrophilic but water insoluble) polymeric materials are known to be useful as bioadhesives and viscosity enhancers. For example, poly(acrylic acids) are used in ophthalmic solutions or mixtures to increase viscosity, thereby increasing the retention time in the eye. An example of a commercially available viscosity enhancer is NOVEON™ AA-1 resins (polycarbophil) available from B.F. Goodrich.

Typically, polymeric viscosity enhancers and bioadhesives decompose, or are otherwise altered, during extended storage periods. The decomposition of a viscosity enhancer reduces the viscosity of the composition, eventually to a point at which the composition is no longer deemed sufficiently effective. Thus, there exists shelf-life problems with compositions, most notably ophthalmic compositions, which include bioadhesives and viscosity enhancers. Accordingly, there is a need to reduce the rate of decomposition of bioadhesives and viscosity enhancers, and to increase the shelf life of compositions including these polymeric materials.

**SUMMARY OF THE INVENTION**

An object of the invention is to provide a means for stabilizing polymeric compositions.

Another object of the invention is to provide a means for reducing the decomposition rate of polymeric bioadhesives and viscosity enhancers.

A further object of the invention is to provide a means for increasing shelf life of ophthalmic compositions which include polymeric components.

- 2 -

One embodiment of the invention is a stabilized composition, which includes at least one polymer selected from the group consisting of bioadhesives and viscosity enhancers, and at least one strong chelating agent (e.g., a phosphonic acid-containing chelating agent) capable of complexing with trace amounts of free catalytic metal ions. The chelating agent is believed to complex with trace amounts of metal ions, thereby reducing the free metal ion concentration. This reduction in free metal ion concentration reduces the decomposition rate of the polymer. The compositions, which are especially useful in the ophthalmic field, exhibit increased shelf life.

Another embodiment of the invention is a method of stabilizing a polymeric composition. The method involves providing an ophthalmically compatible composition including a polymer selected from the group consisting of bioadhesives and viscosity enhancers, adding a strong (e.g., a phosphonic acid-containing) chelating agent to the composition, and allowing the chelating agent to complex with free catalytic metal ions in the composition. The composition exhibits a polymer decomposition rate which is less than the decomposition rate of a composition which does not include a strong chelating agent. Thus, the resultant polymeric composition has an improved shelf life.

Still another embodiment of the present invention is the use of a phosphonic acid containing chelating agent for stabilizing a polymeric composition, wherein the polymer is selected from the group consisting of poly(acrylic acid), an acrylate copolymer, a crosslinked polyacrylic acid, a polysaccharide, and a mixture thereof.

Yet a further embodiment of the present invention is a polymeric composition having a free metal ion concentration less than an amount which will cause substantial polymeric decomposition over a one year storage period at room temperature.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

The compositions of the present invention include a polymeric material, which acts generally as a bioadhesive or a viscosity enhancer, and a stabilizer. The compositions may contain a wide variety of other components, including active agents, excipients, compatibilizers, aesthetic colorants, and the like. A preferred group of compositions are those which are ophthalmically acceptable, i.e., those which do not produce substantial irritation or damage when contacted with the eye, ocular tissue, or surrounding fluids. The preferred ophthalmic compositions are those which are aqueous.

- 3 -

The innovative compositions and methods of the present invention offer improvements in product quality and stability over extended storage periods. Trace amounts of metal ions (e.g., Fe, Cu, Ca, Mg, transition metals), in solutions or slurries, are believed to catalytically increase the decomposition rate of bioadhesive and viscosity enhancing polymers. Metal ions which catalytically decompose bioadhesive and viscosity enhancing polymers are termed "catalytic metal ions" herein. The strong, stable chelating agents of the present invention are believed to complex with the surrounding metal ions, thereby reducing the free metal ions available to degrade the polymer. Thus, the strong, stable chelating agents reduce the rate of degradation, decomposition, or other inactivation of the polymer which results in the viscosity of the composition decreasing over time. As a result, the shelf life of the composition and the viscosity quality after any given extended storage period is improved by the present compositions and methods.

Two theories are offered to explain the improved stability and shelf life of the present compositions to improve the reader's understanding of the invention. However, the invention is not limited by the theoretical explanation of the means by which the invention functions. First, it is believed that the use of chelating agents having an ability to complex with free ions better than EDTA offers improvements in composition stability and shelf life. Increases in strength of the attraction of the chelating agent to metal ions reduces the probability the complex will dissociate to give increased free metal ion concentrations. Second, it is believed that the use of chelating agents which are more chemically stable than EDTA offers improvements in composition stability and shelf life. If the complex degrades, e.g. by oxidation, the metal ion will be released from the complex and will return to solution, where it will increase the polymer degradation rate. Thus, the preferred chelating agents of the present invention have a metal ion complexing strength greater than EDTA and are more stable than EDTA.

Preferred stabilizers of the present invention are a group of chelating agents having phosphonic acid or phosphonate groups. A preferred group of chelating agents are organophosphonates, particularly amino tri(lower alkylene phosphonic acids). A variety of such chelating agents are commercially available from Monsanto Company, St. Louis, Missouri, and are sold under the trademark DEQUEST®. Examples of such compounds include, without limitation, diethylene triamine penta(methylene phosphonic acid); hexamethylene-diaminetetra (methylenephosphonic acid); ethylenediaminetetra (methylene-phosphonic acid); and aminotrimethylene phosphonates. A particularly preferred chelating

- 4 -

agent is diethylene triamine penta(methylene phosphonic acid), sold under the trademark DEQUEST® 2060.

A chelating agent is typically present in an amount of from about 0.00001 to 0.5 weight percent, more preferably in an amount of from about 0.0001 to 0.1 weight percent based on the total weight of a composition..

The bioadhesive or viscosity enhancing polymers of the present invention may be chosen from a wide range of polymers which are susceptible to viscosity reduction (i.e., by degradation or decomposition catalyzed by free metal ions) over time periods of about 30 days to about a year. A preferred group of polymers are those which are cross-linked and have carboxy- and/or hydroxy-functional groups. These bioadhesives or viscosity enhancers include, without limitation thereto, poly(acrylic acids), acrylate copolymers, crosslinked polyacrylic acids, and the like and mixtures thereof. Examples of such a polymeric materials which are commercially available are NOVEON (polycarbophil) resins, e.g. Noveon AA1 (B.F. Goodrich, Cleveland, Ohio), which are water insoluble poly(acrylic acids). Other examples are CARBOPOL® resins, e.g. Carbopol® 940 (B.F. Goodrich) which are water soluble poly(acrylic acids).

Other bioadhesive or viscosity enhancing polymers of the present invention may be chosen from polysaccharides such as e.g. cellulose or a derivative thereof such as hydroxyethyl-cellulose, hydroxyethylcellulose or hydroxypropylcellulose; other polysaccharides such as dextran, hyaluronic acid or chitosan and mixtures thereof.

The amount of a bioadhesive or viscosity enhancing polymer which is present in a composition of the present invention typically depends on its purpose. A composition of the present invention is in particular aqueous and may exhibit a viscosity in the range of from low to high. Accordingly the amount of a bioadhesive or viscosity enhancing polymer present is preferably in the range of from about 0.01 to 20.0 weight %, more preferably in the range of from about 0.05 to 10 weight % and in particular in the range of from about 0.1 to 2.0 weight % based on the total weight of the composition.

In one embodiment, the present compositions are ophthalmic compositions which include a tonicity agent. The tonicity agent is preferably an alkali metal salts, especially sodium chloride. The tonicity agent is present in an amount which is sufficient to achieve an ophthalmically compatible composition. The tonicity agent may be present in an amount

- 5 -

from about 0 to 1.2 weight percent, more preferably about 0.6 to 1.2 weight percent, and most preferably about 0.9 weight percent.

The ophthalmic composition may include an ophthalmic delivery agent. The ophthalmic delivery agents useful in accordance with the present invention may be selected from a wide variety of ophthalmically acceptable agents, including beneficial pharmaceutical agents, diagnostic agents, vitamins, nutrients, lubricants, and the like. The ophthalmic delivery agent may include, without limitation thereto, 3H-thymidine, acetylcholine chloride, acyclovir, adrenaline, amethocaine, aminocaproic acid, antazoline phosphate, arachidonic acid, atropine, benoxinate hydrochloride, betaxolol hydrochloride, bupivacaine, carbachol, carteolol, chloramphenicol, chlortetracycline hydrochloride, chymotrypsin, clonidine, cocaine, corynanthine, cromolyn sodium, cyclopentolate, demecarium bromide, dexamethasone, dibutoline, dichlorphenamide, diclofenac, dipivefrin hydrochloride, echodtiophate iodide, ephedrine, epinephrine bitartrate, erythromycin, ethambutol, etidocaine, eucatropine, fluoromethalone, fluorometholone, gentamicin sulfate, gramicidine, H-thymidine, homatropine hydrobromide, hyaluronic acid, hydrocortisone, idoxuridine, indomethacin, inositol triphosphate, inositol phosphates, isofluorophate, isosorbide, lachesine, levobunolol, levocabastine, lidocaine, lignocaine, medrysone, mepivacaine, methacholine, methazolamide, naphazoline hydrochloride, natamycin, neomycin sulfate, neostigmine, noradrenaline, ofloxacin, oxybuprocaine, oxymetazolin, oxyphenonium, pheniramine maleate, phenylephrine hydrochloride, phosphatidylinositol phosphates, physostigmine, pilocarpine hydrochloride, polyhexamethylene biguanides, polymyxin B sulfates, prednisolone sodium phosphate, proparacaine hydrochloride, proxymethacaine, pyrilamine maleate, scopolamine hydrobromide, sorbinil, sulfacetamide, sulfisoxazole disolamine, tamoxifen, tetracaine hydrochloride, tetracycline, tetrahydrozoline hydrochloride, timolol maleate and hemihydrate, trifluridine, tropicamide, vidarabine, and salts, and other ophthalmically acceptable salts and mixtures thereof.

While the ideal concentration of the ophthalmic delivery agent will depend on a number of factors, the concentration will generally fall within 0.001 and 10 weight percent. Preferably, the ophthalmic delivery agent is present in an amount from about 0.01 to 2.0 weight percent. More preferably, the concentration of ophthalmic delivery agent is about 0.1 to 1.5 weight percent.

The ophthalmic composition may include a demulcent, such as, for example, a glucose biopolymer such as dextran, cellulose or derivatives thereof such as e.g. hydroxyethyl-



- 6 -

cellulose or hydroxypropylcellulose. A preferred glucose biopolymer is dextran. Preferably, the glucose biopolymer is present in an amount from about 0.05 to 5.0 weight percent.

The ophthalmic composition may include other demulcents, such as, for example, a polyalkylene glycol. The polyalkylene glycol is preferably a polyethylene glycol, a polypropylene glycol, or a mixture thereof. Preferably, the polyalkylene glycol is present in an amount from about 0.1 to 2.0 weight percent.

Thus, in a particularly preferred embodiment, the ophthalmic composition includes:

- (a) about 0.01 to 2.0 weight percent of a bioadhesive or viscosity enhancing polymer;
- (b) about 0.0001 to 0.1 weight percent of a chelating agent having at least one phosphonic acid group;
- (c) about 0.1 to 2.0 weight percent poly(alkylene glycol);
- (d) about 0 to 0.9 weight percent of a tonicity enhancer;
- (e) about 0.01 to 5.0 weight percent of a glucose biopolymer;
- (f) about 0.001 to 10 weight percent of a delivery agent; and
- (g) water.

The present method of stabilizing a polymeric compositions, generally includes providing an ophthalmically compatible composition including a bioadhesive or viscosity enhancing polymer; adding at least one strong, stable chelating agent, preferably including at least one phosphonic acid group, to the composition; and allowing the chelating agent to complex with the free metal ions present in the composition, which free metal ions may degrade the polymer, i.e., "catalytic metal ions". This method is believed to allow for the formation of a metal ion complex and polymer formulation which has a decomposition rate which is less than the decomposition rate of the polymer containing trace amounts of free catalytic metal ions.

The order of mixing the components is not believed to be critical. Thus, each of the components of the ophthalmic composition may be, separately and serially, added to a vessel containing water, or all the components may be added simultaneously. Preferably, the components are added separately, with dispersion or dissolution of each separate component being achieved prior to addition of the next component. However, the present stabilization method is not limited by the order of addition or contact of the components.

- 7 -

Accordingly another embodiment of the present invention relates to a process for the manufacture of a stabilized and in particular ophthalmic composition, characterized in that the components of a composition according to the main claim may be, separately and serially, added to a vessel containing water, or all the components may be added simultaneously. In a preferred process the components are added separately, with dispersion or dissolution of each separate component being achieved prior to addition of the next component.

Alkylene means linear or branched alkylene with up to and including 18 C-atoms. Examples are decylene, undecylene and dodecylene. Preferred alkylenes are lower alkylenes.

The term "lower" denotes that the radicals so defined contain up to 8 carbon atoms, preferably up to 6 carbon atoms and more preferably up to 4 carbon atoms.

Accordingly in the present invention lower alkylene means linear or branched alkylene with up to and including 8 C-atoms, more preferably linear or branched alkylene with up to and including 6 C-atoms, and in particular linear or branched alkylene with up to and including 4 C-atoms. Examples are methylene, ethylene, 1,3-propylene, 1,2-propylene, 1,5-pentylene, 1,6-hexylene, 2,5-hexylene, 1,7-heptylene or 1,8-octylene.

The previous disclosure will enable one having ordinary skill in the art to practice the invention. In order to better enable the reader to understand specific embodiments and the advantages thereof, reference to the following examples is suggested.

#### EXAMPLE I

A composition is prepared by mixing NOVEON AA1 (BFGoodrich), sodium chloride, PEG 400 (a 400 molecular weight polyethylene glycol, available from Fisher Scientific), and Dextran 70 (Spectrum Chem. Mfg. Corp., New Brunswick, NJ) in water in amounts sufficient to produce the following weight percentages:

0.625% NOVEON AA1

0.6% NaCl

0.2% PEG 400

0.1% dextran

Q.S. with water

- 8 -

The pH is adjusted to 6.8 by adding diluted sodium hydroxide solution. The viscosity of the composition is measured initially and after exposure to a temperature of about 45 °C for about 13 months. An elevated temperature is used in order to accelerate the stability testing. The results are presented in Table 1.

#### COMPARATIVE EXAMPLE II

A second mixture is prepared by mixing components and adjusting pH as in Example I, with the addition of disodium EDTA (ethylene diamine tetraacetate). The second mixture has the following composition:

0.625% NOVEON AA1  
0.6% NaCl  
0.2% PEG 400  
0.1% Dextran 70  
0.025% disodium EDTA  
Q.S. with water

The composition is adjusted to a pH of about 6.8. The viscosity of the composition is measured initially and after exposure to a temperature of about 45 °C for about 13 months. The results are presented in Table 1.

#### COMPARATIVE EXAMPLE III

A third mixture is prepared by mixing components and adjusting pH as in Example I, with the addition of DEQUEST® 2060 (solids content 50%, Monsanto Company, St. Louis, MO).

The third mixture has the following composition:

0.625% NOVEON AA1  
0.6% NaCl  
0.2% PEG 400  
0.006% DEQUEST® 2060  
0.1% Dextran 70  
Q.S. with water

The composition is adjusted to a pH of about 6.8. The viscosity of the composition is measured initially and after exposure to a temperature of about 45 °C for about 13 months. The results are presented in Table 1.

TABLE 1

Example	Stabilizer	Initial Viscosity (cps)	Viscosity (cps) after 13 mos. at 45 °C
I	none	932.5	250.4
II	0.025% disodium EDTA	924.8	235.0
III	0.006% DEQUEST® 2060	853.3	955.5

#### EXAMPLE IV

A fourth mixture is prepared by mixing components and adjusting pH as in Example I. The fourth mixture has the following aqueous composition, which is substantially the same as the composition of Example I, except that the amount of NOVEON differs slightly:

0.570% NOVEON AA1

0.6% NaCl

0.2% PEG 400

0.1% Dextran 70

Q.S. with water

The composition is adjusted to a pH of about 7. The viscosity of the composition is measured initially and after exposure to a temperature of about 100 °C for about 7 days. The results are presented in Table 2.

#### COMPARATIVE EXAMPLE V

A fifth mixture is prepared by mixing components and adjusting pH as in Example I, with the addition of DEQUEST® 2060. The fifth mixture has the following aqueous composition:

0.570% NOVEON AA1

0.6% NaCl

0.2% PEG 400

0.1% Dextran 70

0.006% DEQUEST® 2060

Q.S. with water

The composition is adjusted to a pH of about 7. The viscosity of the composition is measured initially and after exposure to a temperature of about 100 °C for about 7 days. The results are presented in Table 2.

TABLE 2

Example	Stabilizer	Initial Viscosity (cps)	Viscosity (cps) after 7 days at 100 °C
IV	none	362.8	30.7
V	0.006% DEQUEST® 2060	388.3	373.0

#### DISCUSSION OF RESULTS

Examples I and IV show that the viscosity of poly(acrylic acid) mixtures decreases substantially over time. Example II shows that disodium EDTA does not have a significant impact on the polymer stability.

However, surprisingly, Examples III and V show that poly(acrylic acid) mixtures stabilized with a stabilizer containing phosphonic acid groups does not exhibit significantly reduced viscosity during accelerated test procedures. Further, the DEQUEST® 2060 stabilizer concentration was less than about 12% of the disodium EDTA stabilizer concentration.

The invention has been described in detail, with reference to certain preferred embodiments, in order to enable the reader to practice the invention without undue experimentation. However, a person having ordinary skill in the art will readily recognize that many of the components and parameters may be varied or modified to a certain extent without departing from the scope and spirit of the invention. Furthermore, titles, headings, or the like are provided to enhance the reader's comprehension of this document, and should not be read as limiting the scope of the present invention. Accordingly, the intellectual property rights to this invention are defined only by the following claims and reasonable extensions thereof.

**CLAIMS**

1. A stabilized composition, comprising:
  - (a) at least one polymer selected from the group consisting of bioadhesives and viscosity enhancers; and
  - (b) at least one strong and stable chelating agent, wherein said chelating agent is capable of complexing with free catalytic metal ions, and wherein said chelating agent has a metal ion complexing strength greater than EDTA and said chelating agent is more stable than EDTA.
2. A composition of claim 1, wherein said chelating agent includes at least one phosphonic acid group.
3. A composition of claim 1, wherein said composition is ophthalmically compatible.
4. A composition of claim 3, further including an ophthalmic delivery agent.
5. A composition of claim 4, wherein said ophthalmic delivery agent is selected from the group consisting of ophthalmically beneficial pharmaceutical agents, diagnostic agents, vitamins, nutrients, lubricants, and mixtures thereof.
6. A composition of claim 5, wherein said ophthalmic delivery agent is selected from the group consisting of 3H-thymidine, acetylcholine chloride, acyclovir, adrenaline, amethocaine, aminocaproic acid, antazoline phosphate, arachidonic acid, atropine, benoxinate hydrochloride, betaxolol hydrochloride, bupivacaine, carbachol, carteolol, chloramphenicol, chlortetracycline hydrochloride, chymotrypsin, clonidine, cocaine, corynanthine, cromolyn sodium, cyclopentolate, demecarium bromide, dexamethasone, dibutoline, dichlorphenamide, diclofenac, dipivefrin hydrochloride, echodtiophate iodide, ephedrine, epinephrine bitartrate, erythromycin, ethambutol, etidocaine, eucatropine, fluoromethalone, fluorometholone, gentamicin sulfate, gramicidine, H-thymidine, homatropine hydrobromide, hyaluronic acid, hydrocortisone, idoxuridine, indomethacin, inositol triphosphate, inositol phosphates, isofluorophate, isosorbide, lachesine, levobunolol, levocabastine, lidocaine, lignocaine, medrysone, mepivacaine, methacholine, methazolamide, naphazoline hydrochloride, natamycin, neomycin sulfate, neostigmine, noradrenaline, ofloxacin, oxybuprocaine, oxymetazolin, oxyphenonium, pheniramine

- 12 -

maleate, phenylephrine hydrochloride, phosphatidylinositol phosphates, physostigmine, pilocarpine hydrochloride, polyhexamethylene biguanides, polymyxin B sulfates, prednisolone sodium phosphate, proparacaine hydrochloride, proxymethacaine, pyrilamine maleate, scopolamine hydrobromide, sorbinil, sulfacetamide, sulfisoxazole disolamine, tamoxifen, tetracaine hydrochloride, tetracycline, tetrahydrozoline hydrochloride, timolol maleate and hemihydrate, trifluridine, tropicamide, vidarabine, other ophthalmically acceptable salts thereof and mixtures thereof.

7. A composition of claim 1, wherein said polymer is selected from the group consisting of poly(acrylic acids), acrylate copolymers, crosslinked polyacrylic acids, and mixtures thereof.

8. A composition of claim 7, wherein said polymer is a poly(acrylic acid).

9. A composition of claim 2, wherein said chelating agent is an amino tri(lower alkylene phosphonic acid).

10. A composition of claim 9, wherein said chelating agent is selected from the group consisting of diethylene triamine penta(methylene phosphonic acid); hexamethylene-diaminetetra (methylenephosphonic acid); ethylenediaminetetra (methylenephosphonic acid); aminotrimethylene phosphonates; and mixtures thereof.

11. A composition of claim 10, wherein said chelating agent is diethylene triamine penta(methylene phosphonic acid).

12. A composition of claim 1, comprising:

- (a) about 0.1 to 2.0 weight percent of said polymer;
- (b) about 0.0001 to 0.1 weight percent of said chelating agent; and
- (c) water.

13. A composition of claim 1, further comprising about 0.1 to 2.0 weight percent poly(alkylene glycol).

14. A composition of claim 1, further comprising about 0.6 to 1.2 weight percent of a tonicity enhancer.

15. A composition of claim 14, wherein said tonicity enhancer is sodium chloride.

16. A composition of claim 1, further comprising about 0.05 to 5.0 weight percent of a glucose biopolymer.

17. A composition of claim 16, wherein said glucose biopolymer is dextran.

18. A composition of claim 1, comprising:

- (a) about 0.01 to 2.0 weight percent of said polymer;
- (b) about 0.0001 to 0.1 weight percent of said chelating agent;
- (c) about 0.1 to 2.0 weight percent poly(alkylene glycol);
- (d) about 0 to 1.2 weight percent of a tonicity enhancer;
- (e) about 0.05 to 5.0 weight percent of a glucose biopolymer;
- (f) about 0.001 to 10 weight percent of a delivery agent; and
- (g) water.

19. A composition of claim 18, comprising:

- (a) about 0.01 to 2.0 weight percent of a polymer selected from the group consisting of poly(acrylic acids), acrylate copolymers, crosslinked polyacrylic acids, and mixtures thereof;
- (b) about 0.0001 to 0.1 weight percent of an organophosphorus chelating agent;
- (c) about 0.1 to 2.0 weight percent poly(alkylene glycol) selected from the group consisting of polyethylene glycol, polypropylene glycol, and mixtures thereof;
- (d) about 0 to 1.2 weight percent of an ophthalmically compatible alkali halide tonicity enhancer;
- (e) about 0.05 to 5.0 weight percent of a glucose biopolymer;
- (f) about 0.001 to 10.0 weight percent of a delivery agent; and
- (g) water.

20. A composition of claim 19, wherein said organophosphorus chelating agent is an amino tri(lower alkylene phosphonic acid).

21. A method of stabilizing a polymer composition, comprising the steps of:

- (a) providing an ophthalmically compatible composition including a polymer selected from the group consisting of bioadhesives and viscosity enhancers;
- (b) adding at least one strong and stable chelating agent, wherein said chelating agent is capable of complexing with free metal ions, and wherein said chelating agent has a metal



- 14 -

ion complexing strength greater than EDTA and said chelating agent is more stable than EDTA.; and

(c) allowing said chelating agent to complex with free catalytic metal ions, thereby producing a composition with metal ion complexes, whereby the polymer in said composition has a decomposition rate which is less than the decomposition rate of the uncomplexed composition.

22. A method of claim 21, wherein said chelating agent includes at least one phosphonic acid group.

23. A method of claim 21, further including an ophthalmic delivery agent selected from the group consisting of ophthalmic beneficial pharmaceutical agents, diagnostic agents, vitamins, nutrients, lubricants, and mixtures thereof.

24. A method of claim 21, wherein said chelating agent is an amino tri(lower alkylene phosphonic acid).

25. A method of claim 24, wherein said chelating agent is selected from the group consisting of diethylene triamine penta(methylene phosphonic acid); hexamethylene-diaminetetra (methylenephosphonic acid); ethylenediaminetetra (methylenephosphonic acid); aminotrimethylene phosphonates; and mixtures thereof.

26. A method of claim 25, wherein said chelating agent is diethylene triamine penta(methylene phosphonic acid).

27. A method of claim 21, wherein said polymer composition comprises:

- (a) about 0.1 to 2.0 weight percent of said polymer;
- (b) about 0.0001 to 0.1 weight percent of said chelating agent; and
- (c) water.

28. A method of claim 21, wherein said polymer composition comprises:

- (a) about 0.01 to 2.0 weight percent of said polymer;
- (b) about 0.0001 to 0.1 weight percent of said chelating agent;
- (c) about 0.1 to 2.0 weight percent poly(alkylene glycol);
- (d) about 0 to 1.2 weight percent of a tonicity enhancer;
- (e) about 0.05 to 5.0 weight percent of a glucose biopolymer;

- 15 -

- (f) about 0.001 to 10 weight percent of a delivery agent; and
- (g) water.

29. A method of claim 28, wherein said polymer composition comprises:

- (a) about 0.01 to 2.0 weight percent of a polymer selected from the group consisting of poly(acrylic acids), acrylate copolymers, crosslinked polyacrylic acids, and mixtures thereof;
- (b) about 0.0001 to 0.1 weight percent of an organophosphorus chelating agent;
- (c) about 0.1 to 2.0 weight percent poly(alkylene glycol) selected from the group consisting of polyethylene glycol, polypropylene glycol, and mixtures thereof;
- (d) about 0 to 1.2 weight percent of an ophthalmically compatible alkali halide tonicity enhancer;
- (e) about 0.05 to 5.0 weight percent of a glucose biopolymer;
- (f) about 0.001 to 10 weight percent of a delivery agent; and
- (g) water.

30. An ophthalmically acceptable polymeric composition having a free catalytic metal ion concentration less than an amount which will cause substantial polymeric decomposition over a one year storage period at room temperature.

31. A composition of claim 30, including a chelating agent.

32. A composition of claim 31, wherein said chelating agent is an organophosphorus compound.

33. A composition of claim 32, wherein said organophosphorus compound is diethylene triamine penta(methylene phosphonic acid).

34. A composition of claim 33, wherein said diethylene triamine penta(methylene phosphonic acid) is present in an amount of about 0.0001 to 0.1 weight percent.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 96/02539

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 354 186 (CIBA-GEIGY AG) 7 February 1990  see claims see page 3, line 14 - page 4, line 11 -----	1-4,9, 10,14, 15,21

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

9 October 1996

Date of mailing of the international search report

15. 10. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Scarponi, U

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP 96/02539

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-354186	07-02-90	AT-T- 141803	15-09-96
		AU-B- 628835	24-09-92
		AU-A- 3930389	08-02-90
		DE-D- 68927030	02-10-96
		EP-A- 0706802	17-04-96
		FI-A- 961336	22-03-96
		HR-A- 940515	30-06-96
		JP-A- 2096531	09-04-90
		NO-B- 177626	17-07-95
		PT-B- 91349	04-05-95
-----			

Form PCT/ISA/210 (patent family annex) (July 1992)